Nonsteroidal mineralocorticoid receptor antagonist finerenone ameliorates cardiac hypertrophy with increasing glucocorticoid signaling sensitivity. - Morikawa K; Arima Y; Nagakura T; Xu Y; Fujiyama A; Kataoka M; Hanatani S; Matsuzawa Y; Izumiya Y; Yamamoto E; Tsujita K (Biochemical and biophysical research communications, 2026)